Biography

Dr. Azizul Haque

Department of Microbiol/Immunol

Medical University of South Carolina, USA

Associate Professor

Email: haque@musc.edu

 

Qualifications

1997-2003   Postdoc., Immunol. & Cancer Biol., Indiana Univ. Sch. Med., USA
1993-1997   Ph.D.,  Microbiol. & Immunol, Saga Medical School, Japan
1990-1992   M.S.,  Microbiology, Dhaka University, Bangladesh
1984-1990   B.S.,  Biology, Dhaka University, Bangladesh

   

Publications

  1. Haque MA, Hawes JW, Blum JS (2001) Cysteinylation of an MHC Class II Ligand: importance endocytosis and reductive processing in T cell recognition. J Immunol 166:4543-4551 (PMID 11254711). 
  2. Li P, Haque MA, Blum JS (2002) Role of disulfide bonds in regulating antigen processing and epitope selection.  J Immunol 169:2444-2450 (PMID 12193713).
  3. Haque MA, Li P, Jackson SK, Zarour HM, Hawes JW, Phan UT, Maric M, Cresswell P, Blum JS (2001) Absence of gamma-interferon-inducible lysosomal thiol reductase in melanomas disrupts T cell recognition of select immunodominant epitopes.  J Exp Med 195:1267-1277 (PMID 12021307). 
  4. Haque MA, Mizobuchi T, Yashufuku K, Fujisawa T, Brutkiewicz R, Zheng Y, Woods K, Smith GN, Cummings OW, Heidler KM, Blum JS, Wilkes DS (2002) Evidence for immune responses to a self-antigen in lung transplantation: Role of type v collagen-specific T cells in the pathogenesis of lung allograft rejection.  J Immunol 169:1542-1549 (PMID 12133982). 
  5. Mizobuchi T, Yasufuku K, Zheng Y, Haque MA, Heidler KM, Woods K, Smith GN, Cummings OW, Fujisawa T, Blum JS,  Wilkes DS (2003) Differential expression of Smad7 and TCR V- transcripts identify the CD4-CD45ROhi regulatory T cells that mediate type V collagen-induced tolerance to lung allografts. J Immunol 171:1140-1147 (PMID 12874199). 
  6. O'Donnell PW, Haque A, Klemsz MJ, Kaplan MH, Blum JS (2004) Induction of the antigen processing enzyme IFN-gamma-inducible lysosomal thiol reductase in melanoma cells is STAT1-dependent but CIITA-independent. J Immunol (Cutting Edge) 173:731-735 (PMID 15240658). 
  7. Haque A, Blum JS (2005) New insights in antigen processing and epitope selection: development of novel immunotherapeutic strategies for cancer, autoimmunity and infectious diseases. (Review). J Biol Regul Homeost Agents 19:93-104 (PMID 16602623).  
  8. Srinivasan M, Debao L, Rajaraman E, Brand D, Haque A, Blum JS (2005) CD80 binding polyproline helical peptide inhibits T cell activation. J Biol Chem  280:10149-55 (PMID 15598660). 
  9. Yoshida S, Haque A, Mizobuchi T, Iwata T, Chiyo M, Webb T, Baldridge LA, Heidler KM, Cummings OW, Fujisawa T, Blum JS, Brand DD, Wilkes DS (2006) Anti-type V collagen lymphocytes that express IL-17 and IL-23 induce rejection pathology in fresh and well-healed lung transplants. Am J Transplant 6:724-35 (PMID 16539629). 
  10. Haque A, Das A, Hajiaghamohseni LM, Younger A, Banik NL, Ray SK (2007) Induction of apoptosis and immune response by all-trans retinoic acid plus interferon-gamma in human glioblastoma T98G and U87MG cells. Cancer Immunol Immunother 56:615-25 (PMID 16947022). 
  11. Imam SA, Guyton ML, Haque A, Vandenbark A, Tyor WR, Ray SK, Banik NL (2007) Increased calpain correlates with Th1 cytokine profile in PBMCs from MS patients. J Neuroimmunol 190:139-45 (PMID 17765980).  
  12. Haque A, Banik NL, Ray SK (2007) Emerging role of combination of all-trans retinoic acid and interferon-gamma as chemoimmunotherapy in the management of human glioblastoma. (Review) Neurochem Res 32:2203-9 (PMID 17676389).  
  13. Younger AR, Amria S, Jeffrey WA, Mahdy A, Goldstein OG, Norris JS, Haque A (2008) HLA class II antigen presentation by human prostate cancer cells. Prostate Cancer Prostatic Dis. 11:334-41 (PMID 17938645)
  14. Haque A, Hajiaghamohseni LM, Li P, Toomy K, Blum JS (2007) Invariant chain modulates HLA class II protein recycling and peptide presentation in nonprofessional antigen presenting cells. Cell Immunol 249:20-9 (PMID 18067883). 
  15. Amria S, Cameron CA, Stuart RK, Haque A (2008) Defects in HLA class II antigen presentation in B-cell lymphomas. Leuk. Lymphoma 49:353-5 (PMID 18231926).
  16. Haque A, Banik NL, Ray SK (2008) New insights into the roles of endolysosomal cathepsins in the pathogenesis of Alzheimer’s disease: cathepsin inhibitors as potential therapeutics. (Review) Curr Drug Targets. 7:270-277.
  17. Goldstein OG, Hajiaghamohseni LM, Amria S, Sundaram K, Sakamuri V. Reddy SV, Haque A (2008) Gamma-IFN-inducible-lysosomal thiol reductase modulates acidic proteases and HLA class II antigen processing in melanoma. Cancer Immunol and Immunother. 57:1461-1470 (PMID 18343923). 
  18. Amria S, Hajiaghamohseni LM, Harbeson C, Zhao D, Goldstein O, Blum JS, Haque A (2008) HLA-DM negatively regulates HLA-DR4-restricted collagen pathogenic peptide presentation and T-cell recognition. Eur J Immunol. 38:1961-1970 (PMID: 18506881). 
  19. Norton DL, Haque A (2009) Insights into the role of GILT in HLA class II antigen processing and presentation by melanoma. J Oncololy 2009:142959.  
  20. Doonan BP, Haque A (2010) HLA class II antigen presentation in prostate cancer cells: a novel approach to prostate tumor immunotherapy. Open Cancer Immunology Journal, 3: 1-7. 
  21. God JM, Haque A (2010) Burkitt lymphoma: pathogenesis and immune evasion. J Oncololy, 2010: 516047.  
  22. Johnson BM, Doonan BP, Radwan FF, Haque A (2010) Ganoderic acid DM: an alternative agent for the treatment of advanced prostate cancer. Open Prostate Journal 3:78-85. 
  23. Haque A, Banik NL, Ray SK (2011). Molecular alterations in glioblastoma: potential targets for immunotherapy. Prog Mol Biol Transl Sci. 98:187-234. 
  24. Smith AW, Doonan BP, Haque A, Banik NL (2011) Regulation of Th1/Th17 cytokines and IDO by inhibition of calpain in PBMCs from MS patients. J Neuroimmunology. 232(1-2):179-85 
  25. Hathaway JD and Haque A (2011) Insights into the role of PAX-3 in the development of melanocyte and melanoma. Open Cancer Journal 4:1-6. 
  26. Zhao D, Amria S, Hossain A, Sundaram K, Komlosi, Nagarkatti M, Haque A (2011) Enhancement of HLA class II-restricted CD4+ T cell recognition of human melanoma cells following treatment with bryostatin-1. Cell Immunol 271(2):392-400. 
  27. Radwan F, Lixia Z, Hossain A, Doonan BP, God J, Haque A (2011) Mechanisms regulating enhanced HLA class II-mediated CD4+ T cell recognition of human B-cell lymphoma by resveratrol, Leuk Lymphoma (In press) 
  28. Hossain A, God JM, Radwan FF, Amria S, Zhao D, Bethard JR, Haque A (2011) HLA class II defects in Burkitt lymphoma: bryostatin-1-induced 17 kDa protein restores CD4+ T cell recognition. Clinical and Developmental Immunology (In press)

Profile Details   

Last Updated: December 9, 2011.

Reference this profile directly: Null

 

 

Free SCIRP Newsletters
Copyright © 2006-2022 Scientific Research Publishing Inc. All Rights Reserved.
Top